Delivery ceremony attended by senior Panama health officials; devices to be deployed at key public medical facilities

Medical device approval secured, paving way for entry into national cancer screening program

Fully automated compact device handles staining through AI analysis; Latin America public health expansion accelerates

Senior Panamanian government officials and Noul representatives pose for a photo at the delivery ceremony for Noul's cervical cancer diagnostic solution, miLab CER. [Noul]
Senior Panamanian government officials and Noul representatives pose for a photo at the delivery ceremony for Noul's cervical cancer diagnostic solution, miLab CER. [Noul]

Noul, an AI-based blood and cancer diagnostics company, will officially supply its AI cervical cancer diagnostic solution to Panama's national public health system.

Noul announced Monday that it held an official delivery ceremony Thursday (local time) for miLab CER, its AI-based cervical cancer diagnostic solution aimed at enabling early detection of cervical cancer among women across Panama.

The ceremony was attended by Fernando Boyd Galindo, Panama's Minister of Health (MINSA), officials from the presidential office, South Korean Ambassador to Panama Han Byung-jin, and representatives from the National Center for Cytopathology Diagnostics (CERCID).

On Noul's side, Chief Operating Officer Ahn Jeong-kwon attended alongside business development staff for Latin America and executives from the local distribution partner.

The miLab CER units delivered will be deployed at key public health facilities that serve as central nodes in Panama's cervical cancer diagnostic network. The devices are expected to support medical professionals in reading test results through miLab's automated workflow and AI-based specimen analysis, helping establish an early screening system.

Noul recently obtained medical device regulatory approval from Panama's health authorities for miLab CER, laying the legal groundwork for official supply. Building on this entry into the national public health system, the company plans to strengthen formal ties with the national cancer screening program and expand follow-on supply of equipment and diagnostic cartridges to local medical institutions.

miLab CER is a point-of-care solution that fully automates the entire process — from staining cervical cell slides to digital imaging and AI analysis — within a single compact device. The solution has drawn attention in Latin American public health settings for its ability to improve diagnostic accuracy and speed even in areas lacking specialist pathology staff and basic medical infrastructure.

Founded in 2015, Noul is an on-device AI healthcare company that developed miLab, a decentralized diagnostic platform capable of automatically completing cartridge preprocessing, imaging and AI analysis in an average of 15 minutes. The platform is now supplied in more than 30 countries worldwide.

"This delivery ceremony, attended by Panama's top government and health officials, signals that Noul's technology has been recognized as a core solution for addressing public health challenges at the national level," said Lim Chan-yang, chief executive of Noul. "Through our partnership with the local health ministry and national diagnostic institutions, we will work to improve early cancer detection rates and use this as a model reference to expand our public health business across Latin America."


silverpaper@heraldcorp.com